With a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.
Will Lewis, CEO of New Jersey-based Insmed Incorporated, believes this year will be transformational for the company, not least because it has several parallel late-stage clinical programs reaching maturation.
“We’re stacking a lot of events on top of each other that are quite significant for the company,” Lewis told...
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Exec summary XXXXXXX
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
